"If it ain't broke, don't fix it": A commentary on the positive-negative results of the ACCORD Lipid study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Tenenbaum, Alexander ^a,b,c   Fisman, Enrique Z ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cardiovascular Diabetology Research Foundation   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG MEGADOSE; DYSLIPIDEMIA; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PREVALENCE; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; ARTICLE; BLOOD; DRUG COMBINATION; EVIDENCE BASED MEDICINE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIMVASTATIN; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77954254329     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-24     Document Type: Note

References (34)

1. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. 10.1056/NEJMoa1001282, 20228404, ACCORD Study Group.
2. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20. 10.1186/1475-2840-5-20, 1592077, 17002798.
3. Garg A, Simha V. Update on dyslipidemia. J Clin Endocrinol Metab 2007, 92:1581-1589. 10.1210/jc.2007-0275, 17483372.
4. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414. 10.1007/s10557-005-5686-z, 16453090.
5. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. 10.1056/NEJMoa040583, 15007110.
6. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, . A to Z Investigators Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316. 10.1001/jama.292.11.1307, 15337732, A to Z Investigators.
7. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, . Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. 10.1056/NEJMoa050461, 15755765, Treating to New Targets (TNT) Investigators.
8. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, . Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445. 10.1001/jama.294.19.2437, 16287954, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.
9. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J 2007, 154:815-823. 10.1016/j.ahj.2007.06.034, 17967584.
10. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol 2008, 45:127-153. full_text, 18230960.
11. Sacks FM, . for the Expert Group on HDL Cholesterol The role of high-density lipoprotein [HDL] cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol 2002, 90:139-143. 10.1016/S0002-9149(02)02436-0, 12106843, for the Expert Group on HDL Cholesterol.
12. Fruchart JC. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol 2001, 88:24N-29N. 10.1016/S0002-9149(01)02149-X, 11788127.
13. Verges B. Clinical interest of PPARs ligands. Diabetes Metab 2004, 30:7-12. 10.1016/S1262-3636(07)70083-6, 15029092.
14. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
15. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418. 10.1056/NEJM199908053410604, 10438259.
16. Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Am J Cardiol 1997, 80:1125-1129. 10.1016/S0002-9149(97)00626-7, 9359536.
17. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD. Cardiovascular outcomes in type 2 diabetes. A double-blind placebocontrolled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998, 21:641-648. 10.2337/diacare.21.4.641, 9571357.
18. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002, 325(7373):1139. 10.1136/bmj.325.7373.1139, 133451, 12433762.
19. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27.
20. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomized study. Lancet 2001, 357:905-910. 10.1016/S0140-6736(00)04209-4, 11289345.
21. Tenenbaum A, Motro M, Fisman EZ, Tanne, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160. 10.1001/archinte.165.10.1154, 15911729.
22. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45.
23. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department ofV eterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604. 10.1001/archinte.162.22.2597, 12456232.
24. Tenkanen L, Manttari M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006, 166:743-748. 10.1001/archinte.166.7.743, 16606810.
25. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14. 10.1186/1475-2840-4-14, 1236941, 16168052.
26. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741. 10.1001/archinte.166.7.737, 16606809.
27. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202. 10.1161/01.CIR.0000126824.12785.B6, 15123532.
28. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038. 10.1093/eurheartj/ehi310, 15872029.
29. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, Motro M, Tenenbaum A. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-71. 10.1016/j.atherosclerosis.2006.08.005, 16970952.
30. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, . Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498. 10.2337/dc08-1543, 2646035, 18984774, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.
31. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375(9729):1875-8. 10.1016/S0140-6736(10)60656-3, 20462635.
32. O'Riordan M. ACCORD: Fenofibrate no benefit to statin therapy in high-risk diabetic patients. Heartwire 2010, , http://www.theheart.org/article/1054681.do
33. Syvänne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997, 350(Suppl 1):SI20-123.
34. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210-1214. 10.2337/diabetes.52.5.1210, 12716754.